BETHLEHEM, PA—June 5, 2018 — FamilyWize announced today a partnership that will give the public greater
access to personalized medicine, helping patients better understand how their unique genetic profiles can
influence how they metabolize certain medications. As part of this effort, FamilyWize has partnered with
MedTek21, a software-based platform that helps both patients and their care providers identify hidden medication
risks and optimize prescribed medications for maximum efficacy.
FamilyWize and MedTek21 can help patients by offering access to MedTek21 Direct, an easy-to-use personalized medication management program. This program can help patients learn if they have been prescribed a medication that might be impacted by their unique metabolic profile. MedTek21’s software and mobile application continuously keep patients and their physicians up to date and proactively flag any new potential issues in real time. Should a prescribed medication be indicated to not improve the patient’s health, this means money is being spent on a potentially ineffective prescription with each monthly refill.
To learn more, patients can visit https://familywize.org/commercial-partners/medtek21. Within a few days of submitting basic medication information to MedTek21, the patient and their care provider will receive actionable data and clear summary reports highlighting potential issues based on currently prescribed medications. MedTek21 also provides the latest information about the patient’s potential reactions to an expanding list of over 250 common medication compounds and incorporates the latest in FDA prescribing guidelines and clinical research.
The partnership potentially enables consumers to experience positive results both physically and financially. The patient’s care providers can easily interpret MedTek21 Direct results to increase the efficiency of drug therapy through adjustments in the medication or medication dosages. In addition, patients can save significantly on the safest and most effective medications through FamilyWize and avoid the need to waste time and money on potentially ineffective medications.
“The prescribing of medications which are metabolized abnormally by certain patients is a growing problem, and these patients are suffering physically and financially as a result,” said Joseph Sanginiti, President and Chief Executive Officer of FamilyWize. “As advocates for the physical and financial well-being of all Americans, FamilyWize is addressing the issue head-on. Our partnership with MedTek21 will offer patients easy access to details on their unique genetic profiles and enable physicians to more accurately determine affordable treatment options. Together we will expand awareness of MedTek21 Direct and the positive impact of personalized medicine on savings and overall health.”
“We’re very pleased to announce this partnership with FamilyWize,” said Steve Salvitti, CEO of MedTek21. “Millions of FamilyWize users who have benefited from lower cost medications will now also have access to MedTek21’s mobile application, risk assessment tools, proactive recommendations, and clinical support team to analyze and remediate drug-to-gene risks. FamilyWize has a proud history of innovations that empower patients to play a role in the management of both their care and their care costs, and this partnership will truly help patients to get the best medication, at the optimal dose, and at the best price.”